Abraham Ceesay

President, Cerevel Therapeutics

Abraham Ceesay currently serves as the president of Cerevel Therapeutics . Abe has over 17 years of experience in leading biopharmaceutical companies and commercializing innovative therapeutic products.

Prior to joining Cerevel, he served as chief executive officer at Tiburio Therapeutics. He also served as chief operating officer at scPharmaceuticals where he developed and led all operational and commercial aspects of the company. He was integral in raising more than $140 million in private and public capital as well as closing the company’s initial public offering. Prior to joining scPharmaceuticals, he served as vice president, sales, marketing, and commercial operations at Keryx Biopharmaceuticals and spent four years at Ironwood Pharmaceuticals as vice president of marketing. He also held responsibility for the management of the U.S. P&L, leadership of the Linzess® brand team and co-promotion collaboration with Forest Laboratories/Allergan. Previously, Abraham was at Genzyme/Sanofi, initially as a field sales specialist and ultimately as the director, Renal Global Marketing, in which capacity he led the global launch of Renvela® and held global marketing responsibility for the company’s renal franchise (Renagel®, Renvela®, Hectorol®).

Abraham serves on the Board of Advisors for Life Science Cares and the Board of Directors for Food for Free and Camp Harbor View. He holds a bachelor’s degree from Ithaca College, and a Master of Business Administration from Suffolk University’s Sawyer School of Management.